dc.contributor.author |
Cholo, Moloko C.
|
|
dc.contributor.author |
Steel, Helen C.
|
|
dc.contributor.author |
Fourie, P.B. (Petrus Bernardus)
|
|
dc.contributor.author |
Germishuizen, Willem Andreas
|
|
dc.contributor.author |
Anderson, Ronald
|
|
dc.date.accessioned |
2012-03-14T11:31:01Z |
|
dc.date.available |
2013-02-28T00:20:03Z |
|
dc.date.issued |
2012-02 |
|
dc.description.abstract |
Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-inflammatory activities. However, its efficacy has been demonstrated only in the treatment of leprosy, not in human
tuberculosis, despite the fact that this agent is impressively active in vitro against multidrug-resistant strains of Mycobacterium tuberculosis. Recent insights into novel targets and mechanisms of antimicrobial and antiinflammatory activity coupled with the acquisition of innovative drug delivery technologies have, however, rekindled interest in clofazimine as a potential therapy for multidrug- and extensively multidrug-resistant tuberculosis in particular, as well as several autoimmune diseases. The primary objective of this review is to critically evaluate these recent developments and to assess their potential impact on improving the therapeutic efficacy and versatility of clofazimine. |
en_US |
dc.description.sponsorship |
The South African Medical Research Council.
Research into the spray-dried formulations of clofazimine is supported by
the K-RITH collaborative grant (Howard Hughes Medical Institute and the
University of KwaZulu-Natal). |
en_US |
dc.description.uri |
http://jac.oxfordjournals.org/ |
en_US |
dc.identifier.citation |
Cholo, MC, Steel, HC, Fourie, PB, Germishuizen, WA & Anderson, R 2012, 'Clofazimine: current status and future prospects', Journal of Antimicrobial Chemotherapy, vol. 67, no. 2, pp. 290-298. |
en_US |
dc.identifier.issn |
0305-7453 (print) |
|
dc.identifier.issn |
1460-2091 (online) |
|
dc.identifier.other |
10.1093/jac/dkr444 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/18427 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Oxford University Press |
en_US |
dc.rights |
© The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The definitive publisher-authenticated version of Cholo, MC, Steel, HC, Fourie, PB, Germishuizen, WA & Anderson, R 2012, 'Clofazimine: current status and future prospects', Journal of Antimicrobial Chemotherapy, vol. 67, no. 2, pp. 290-298 is available online at: jac.oxfordjournals.org/content/67/2/290. This article is embargoed by the publisher until February 2013. |
en_US |
dc.subject |
Anti-inflammatory activity |
en_US |
dc.subject |
Leprosy |
en_US |
dc.subject |
Lysophospholipids |
en_US |
dc.subject |
Membrane destabilization |
en_US |
dc.subject |
Mycobacteria |
en_US |
dc.subject |
Potassium transporters |
en_US |
dc.subject |
Reactive oxygen species |
en_US |
dc.subject |
Redox cycling |
en_US |
dc.subject |
Spray-drying |
en_US |
dc.subject |
Tuberculosis |
en_US |
dc.subject |
T lymphocytes |
en_US |
dc.subject.lcsh |
Tuberculosis -- Vaccination |
en |
dc.title |
Clofazimine : current status and future prospects |
en_US |
dc.type |
Postprint Article |
en_US |